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Abstract 
Background: The European Organisation for Research and Treatment of Cancer (EORTC) 
62012 study was a phase III trial of doxorubicin versus doxorubicin-ifosfamide 
chemotherapy in 455 patients with advanced soft tissue sarcoma (STS).  Analysis of the main 
study showed that combination chemotherapy improved tumour response and progression 
free survival, but differences in overall survival (OS) were not statistically significant.  We 
analysed factors prognostic for tumour response and OS, and assessed histological subgroup 
and tumour grade as predictive factors to identify patients more likely to benefit from 
combination chemotherapy. 
Methods: Central pathology review was performed by six reference pathologists. Gender, 
age, performance status, time from first presentation with sarcoma to starting palliative 
chemotherapy, tumour grade, histological subgroup, and site of metastases were assessed as 
prognostic factors. 
Results: 310 patients were included in this study. Discordance between local and central 
pathology opinion of tumour histology and tumour grade was observed in 98 (32%) and 122 
(39%) cases respectively. In multivariate analysis, liposarcoma patients had improved tumour 
response compared to other histological subgroups, whilst patients with metastases other than 
lung, liver or bone had a poorer response (odds ratio (OR) 0.42, 95%CI 0.23 ± 0.78; 
p=0.006). Patients with bone metastases had reduced OS (hazard ratio (HR) 1.56, 95%CI 
1.16 ± 2.09; p=0.003).  By central pathology review, patients with undifferentiated 
pleomorphic sarcoma (UPS) had improved tumour response and OS with doxorubicin-
ifosfamide compared to single-agent doxorubicin (OR 9.90, 95% CI 1.93 ± 50.7 and HR 0.44, 
95%CI 0.26 ± 0.79 respectively). Grade III tumours had improved response with combination 
chemotherapy but there was no interaction between chemotherapy and grade on OS.     
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Conclusions: Prospective central pathology review of tumour histology should be integrated 
into future STS clinical trials. Doxorubicin-ifosfamide may be most appropriate for young, fit 
patients with advanced grade III UPS.  
 
Keywords: Soft tissue sarcoma; chemotherapy; prognostic factors; predictive factors 
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Introduction 
Soft tissue sarcomas (STS) are a group of rare aggressive tumours of mesenchymal origin, 
separated into over 50 different subtypes by histological and molecular classifications 1,2. 
Chemotherapy is the mainstay of treatment for patients with unresectable metastatic disease, 
and is usually administered with palliative intent. Doxorubicin and ifosfamide have single-
agent activity in STS 3,4, but the role of combination doxorubicin-ifosfamide has been less 
certain. The European Organisation for Research and Treatment of Cancer (EORTC) 62012 
study was a multi-centre randomised phase III trial of first-line single-agent doxorubicin vs 
intensified doxorubicin-ifosfamide chemotherapy for young, fit patients with advanced 
intermediate or high grade STS 5. Combination chemotherapy was associated with a 
significantly higher tumour response rate (complete + partial response, 26% vs 14%; 
p<0.0006) and improved progression free survival (PFS, hazard ratio (HR) 0.74, 95% 
confidence intervals (CI) 0.60 ± 0.90; p=0.003), but overall survival (OS) was not 
significantly different (HR 0.83, 95% CI 0.67 ± 1.03; p=0.076). Furthermore, combination 
chemotherapy was associated with significantly more toxicity (Grade 3-4 febrile neutropenia 
46% vs 13%; p<0.0001). The study authors concluded that single-agent doxorubicin was 
appropriate for the majority of patients with advanced STS, however combination 
chemotherapy was justified for select patients in whom the primary aim of treatment was 
tumour shrinkage, to alleviate symptoms or to enable local disease control by subsequent 
surgery or radiotherapy. 
A previous meta-analysis of seven heterogeneous EORTC-led clinical trials of first-line 
anthracycline-based chemotherapy for advanced STS reported younger age, good 
performance status (PS) and absence of liver metastases as prognostic of both improved 
tumour response to chemotherapy and OS 6. Higher tumour grade and liposarcoma histology 
were other factors associated with improved tumour response to chemotherapy, whilst low 
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tumour grade and longer time elapsed from initial diagnosis of sarcoma to starting first-line 
chemotherapy were associated with improved OS.  
We performed an analysis of the EORTC 62012 study to validate factors prognostic of 
tumour response to chemotherapy and OS in patients with advanced STS treated in a 
contemporary prospective randomised phase III clinical trial. We then explored histological 
subtype and tumour grade as predictive factors to identify patient subgroups more likely to 
benefit from treatment with combination chemotherapy. 
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Methods 
Patients included in the subgroup analysis: 
455 patients were recruited to the EORTC 62012 study (NCT00061984). The detailed 
eligibility criteria for the EORTC 62012 study have previously been published 5, including 
age \HDUV:+2SHUIRUPDQFHVWDWXV36RUDQGLQWHUPHGLDWHRUKLJKJUDGH676E\
local pathology opinion. Patients who received at least one cycle of chemotherapy were 
eligible for the subgroup analysis. A central pathology review of tumour histology and 
tumour grade was performed by six expert STS pathologists according to the World Health 
Organisation 2013 classification of tumours of soft tissue and bone 1 and the French 
Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) system 7 
respectively. Cases without central pathology review, or without sarcoma histology, or where 
tumour grade was low or not assessable by central pathology review, or who did not meet 
other eligibility criteria for the main study were excluded (figure 1). The study population 
thereby consisted of 310 patients with characteristics similar to the main study population 
(table 1). 
Histological subtypes were pooled for analysis into liposarcoma, leiomyosarcoma, synovial 
sarcoma, undifferentiated pleomorphic sarcoma (U36RUµRWKHU¶VXEJURXSV*HQGHUDJH
PS, time elapsed from initial presentation with sarcoma to starting palliative chemotherapy, 
WXPRXUJUDGHKLVWRORJLFDOVXEJURXSDQGVLWHRIPHWDVWDVHVOLYHUOXQJERQHDQGµRWKHU¶
were assessed as factors prognostic for tumour response to chemotherapy and OS. Patients 
were included in the prognostic factor analysis based on central pathology review.  
Histological subgroup and tumour grade were then assessed as factors predictive of improved 
tumour response and OS with combination chemotherapy. In this exploratory analysis, 
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histological subgroup and tumour grade were analysed according to both local and central 
pathology assignment. 
Statistics: 
Response to chemotherapy was reported based on local investigator assessment according to 
RECIST 1.0 8. Overall survival was computed from the date of randomization in the study to 
the date of death. Patients still alive at the time of the analysis were censored at their last 
follow-up date or the clinical trial cut-off date, whichever occurred first. Analyses for 
response rate (complete + partial response) were performed using logistic regression; 
analyses for overall survival were performed using Cox regression models. Factors included 
in the final multivariate models were identified using stepwise selection. A significance level 
of 0.15 was required to include a factor in the multivariate model, and a significance level of 
0.05 was required for a factor to stay in the model.  
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Results 
Central pathology review of tumour histology was available for 354/455 cases (78%). 
Discordance with local assessment was observed in 118 cases (33%), including six patients 
who did not have STS histology on central review. Central pathology review of tumour grade 
was available for 339/455 cases (75%). Discordance with local assessment was observed in 
141 cases (42%). After excluding patients that failed other eligibility criteria, 310 patients 
were included in the subgroup analysis. Of these 310 patients, discordance between local and 
central pathology assessment of tumour histology and tumour grade was observed in 98 
(32%) and 122 (39%) cases respectively. Consistent with the main study results, combination 
chemotherapy was associated with improved tumour response (odds ratio (OR) 2.44, 95% CI 
1.38 ± 4.31; p=0.002), but OS was not significantly different (HR 0.82, 0.64 ± 1.04; 
p=0.105).   
Prognostic factor analysis: 
In multivariate analysis, gender, age, PS, time from first presentation with sarcoma to starting 
palliative chemotherapy, tumour grade, histological subgroup, and sites of metastases were 
assessed as potential factors prognostic for tumour response to chemotherapy and OS. Central 
pathology review of histology and tumour grade were used for this analysis. 
,QERWKXQLYDULDWHDQGPXOWLYDULDWHDQDO\VLVOLSRVDUFRPDKLVWRORJ\DQGµRWKHU¶PHWDVWDWLF
disease sites were prognostic for tumour response to chemotherapy (table 2). Patients with 
liposarcoma had improved tumour response to chemotherapy compared to other histological 
subgroups (overall p=0.014), whilst patients with metastases at sites other than lung, liver or 
bone had poorer tumour response to chemotherapy (OR 0.42, 95% CI 0.23 ± 0.78; p=0.006). 
µ2WKHU¶PHWDVWDWLFGLVHDVHVLWHVLQFOXGHGO\PSKQode metastases (92 cases), skin metastases 
(9 cases) and other soft tissue metastases (77 cases). Grade III tumours were associated with 
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improved tumour response to chemotherapy, but this was not statistically significant (OR 
1.43, 95% CI 0.76 ± 2.67).  
In univariate analysis, PS 1 (HR 1.37, 95% CI 1.06 ± 1.77; p=0.017), shorter time from initial 
presentation with sarcoma to starting palliative chemotherapy (HR 1.49, 95% CI 1.08 ± 2.07; 
p=0.014), and presence of bone metastases (HR 1.44, 95% CI 1.00 ± 2.07; p=0.052) were 
associated with reduced OS. However, only bone metastases remained statistically significant 
(HR 1.56, 95% CI 1.16 ± 2.09; p=0.003) in the final multivariate model (table 3).  
Predictive factor analysis: 
Tumour grade (grade II or III) and histological subtype, grouped into liposarcoma, 
OHLRP\RVDUFRPDV\QRYLDOVDUFRPD836RUµRWKHU¶ZHUHDVVHVVHGDVSUHGLFWLYHIDFWRUV
Outcomes differed depending on local or central pathology assignment of histological 
subtype (table 4). By local pathology DVVHVVPHQWRIKLVWRORJ\V\QRYLDOVDUFRPDVDQGµRWKHU¶
subgroups had a higher response rate with combination chemotherapy compared to single-
agent doxorubicin (43.5% vs 11.1% (OR 6.15, 95% CI 1.43 ± 26.39) and 29.0% vs 10.5% 
(OR 3.48, 95% CI 1.27 ± 9.53) IRUV\QRYLDOVDUFRPDDQGµRWKHU¶UHVSHFWLYHO\ZKLOVWWXPRXU
response rates for liposarcoma, leiomyosarcoma and UPS subgroups did not differ 
significantly by treatment arm. In contrast, by central pathology assessment, the UPS 
subgroup had a higher response rate with combination chemotherapy than with single-agent 
doxorubicin (42.3% vs 6.9% (OR 9.90, 95% CI 1.93 ± 50.7)), but response did not differ 
significantly between treatment arms for liposarcoma, leiomyosarcoma, synovial sarcoma or 
µRWKHU¶VXEJURXSV Analysis of OS by local pathology assessment showed no interaction 
between histological subgroup and treatment arm, whilst patients with UPS by central 
pathology review had improved OS with combination chemotherapy compared with single-
agent doxorubicin (HR 0.44, 95% CI 0.26 ± 0.79) (figure 2).  
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Irrespective of local or central pathology assessment, grade III tumours had an improved 
response rate with combination chemotherapy compared with single-agent doxorubicin (OR 
2.93, 95% CI 1.30 ± 6.61 and 3.64, 95% CI 1.72 ± 7.70 by local and central pathology 
assessment respectively). Response rate in grade II tumours by either local or central 
pathology assessment did not differ significantly by treatment arm. No interaction between 
treatment arm and tumour grade was identified in OS analysis, irrespective of local or central 
pathology assessment of grade. 
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Discussion 
We observed a substantial discordance between local pathology assessment and central 
pathology expert review of histological subtype and tumour grade. This degree of 
discordance is consistent with levels reported by other STS studies 9-13. STS pathology is 
highly complex, and the classifications of STS subtypes are constantly evolving. Despite the 
growing role of molecular pathology to facilitate diagnosis, the identification of STS 
subtypes still largely relies on interpretation of tumour morphology and 
immunohistochemistry. Central pathology review therefore fulfils an important role in 
verifying the diagnosis. In contrast to local pathology opinion, which may be refined by 
access to additional tumour samples and clinical and radiological correlates, central 
pathology assessment was wholly dependent on the specimen submitted for review. As STS 
tumours contain areas of heterogeneity, this explains some of the discordance observed 
between local and central pathology opinions.  
The eligibility criteria of previous clinical trials in STS frequently included patients with a 
variety of different histological subtypes. However, as treatments of individual subtypes are 
progressively refined, clinical trials increasingly recruit STS patients with specific 
histological subtypes. The EORTC 62043 study, a single-arm phase II trial of pazopanib in 
patients with advanced STS for example, assessed treatment response in four histological 
FRKRUWVRI676OHLRP\RVDUFRPDOLSRVDUFRPDV\QRYLDOVDUFRPDDQGµRWKHUV¶14. On the 
basis of this study, patients with liposarcoma were excluded from the subsequent phase III 
PALETTE trial 15. Different conclusions could be drawn from our subgroup analysis of 
histological subtype as a predictive factor of response to combination chemotherapy, 
dependent on whether local pathology or central pathology assessment of tumour histology 
was used. This analysis was exploratory, and was limited by small numbers of patients in 
each histological subgroup, but it highlights the importance of accurate pathology 
12 
 
classification in STS studies, and suggests a role for incorporating mandatory prospective 
central pathology review into future trial protocols. This should become possible in practice 
as shared digital platforms become increasingly common. 
2XUDQDO\VLVVXJJHVWHGWKDW836V\QRYLDOVDUFRPDDQGµRWKHU¶KLVWRORJLFDOVXEW\SHVZHUH
most likely to respond to treatment with combination chemotherapy. The histological 
VXEJURXSODEHOOHGµRWKHU¶HQFRPSDVVHGDSRROHGFROOHFWLRQRIUDUHU676VXEW\SHVZLWK
diverse pathologies. Together, this subgroup represented a third (104/310) of all patients 
included in this analysis, which individually were too infrequent to be analysed separately. 
Only UPS by central review classification had improved OS with combination chemotherapy. 
Interestingly, a contemporary study of peri-operative epirubicin + ifosfamide chemotherapy 
in localised high-risk soft tissue sarcomas of the trunk and extremities also reported improved 
OS outcomes in UPS compared to other histological subtypes 16. The lack of OS advantage 
ZLWKFRPELQDWLRQFKHPRWKHUDS\LQV\QRYLDOVDUFRPDDQGµRWKHU¶VXEW\SHVGHVSLWHLPSURYHG
tumour response rates is consistent with a separate analysis of the EORTC 62012 study, 
which demonstrated that the absence of tumour progression and not the extent of disease 
remission defines prognosis in STS 17. Synovial sarcomas are considered to be 
chemosensitive tumours. Previous studies have suggested that synovial sarcomas have higher 
responses rates to chemotherapy than other STS subtypes, including improved response rates 
to regimens containing ifosfamide 18. UPS are aggressive high grade tumours with no 
discernable histological differentiation 19. They are diagnosed by exclusion of other 
pleomorphic subtypes, including leiomyosarcoma and liposarcoma. Samples identified as 
UPS on central pathology review therefore include poorly differentiated STS subtypes, which 
have been re-classified on the basis of the submitted specimen. Such poorly differentiated 
tumours may have aggressive tumour biology that benefit more from combination 
chemotherapy. This would support the parallel observation that high grade tumours were 
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more likely to respond to combination chemotherapy than intermediate grade lesions, 
although tumour grade did not influence OS.  
We used central pathology assessment of tumour histology and tumour grade for the 
prognostic factor analysis, as this had been undertaken by a small panel of expert sarcoma 
pathologists. The prognostic factor analysis identified that liposarcoma histology was 
associated with improved tumour response rate compared to other histological subgroups. 
Previous studies have also suggested that liposarcomas are associated with a higher response 
rate 6. The liposarcoma subgroup consisted of disparate subtypes including dedifferentiated 
liposarcoma, pleomorphic liposarcoma and myxoid liposarcoma. Myxoid liposarcomas are 
considered chemosensitive, whilst dedifferentiated liposarcomas are considered less sensitive 
to chemotherapy. Unfortunately, the specific liposarcoma subtype present was not recorded 
centrally, and analysis to refine tumour response rate by liposarcoma subtype was not 
possible, although the small number of liposarcoma patients included in the study (25 cases 
by central pathology review) would have limited more detailed analysis.      
PS is a well-established prognostic factor 20. The EORTC 62012 study recruited patients aged 
ZLWK:+2PS 0 or 1. It is therefore striking that PS was prognostic of OS despite 
eligibility criteria restricting the study population to young fit patients. Time between initial 
diagnosis of sarcoma and commencing palliative chemotherapy has previously been 
identified as prognostic 6. Patients with a shorter time to starting palliative chemotherapy 
from initial diagnosis (3 ± 12 months) had worse OS.  This cohort consisted of patients with 
poor tumour biology and rapidly progressive disease. A longer interval between initial 
diagnosis and starting chemotherapy (>12 months) implied less aggressive disease and was 
associated with improved OS, whilst patients presenting with metastatic disease (interval 
from initial diagnosis <3 months) represented a mix of these two patient populations. The 
presence of bone metastases was the only factor prognostic for OS in the final multivariate 
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model. Bone metastases were reported in 44/310 (14.1%) patients included in the subgroup 
analysis. A previous multi-centre retrospective analysis identified bone metastases as a poor 
prognostic feature, and suggested routine use of bisphosphonate therapy for patients with 
metastatic bone disease to delay the onset of skeletal related events (e.g. pathological 
fracture, spinal cord compression, or hypercalcaemia) 21. 
In summary, we performed an analysis of the EORTC 62012 study, a large phase III trial of 
single-agent doxorubicin versus a doxorubicin-ifosfamide combination for advanced STS. 
This subgroup analysis highlights the importance of the sarcoma pathologist to the 
assessment of clinical trial outcomes. Single-agent doxorubicin remains standard of care first-
line chemotherapy for patients with advanced soft tissue sarcoma. However, combination 
doxorubicin-ifosfamide is indicated for selected patients, and this analysis suggests 
FRPELQDWLRQWUHDWPHQWPD\EHPRVWDSSURSULDWHWRFRQVLGHULQSDWLHQWV\UVROG36RU
with poorly differentiated, grade III tumours including UPS. 
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Figure 1: Subgroup analysis flow chart 
 
Figure 2: Interaction of histological subtype with treatment on overall survival (A: central pathology 
review; B: local pathology review) 
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Table 1: Patient characteristics 
 
Analysis population 
All 
patients 
(N=455) 
All 
eligible 
patients 
(N=310) 
 N (%) N (%) 
Treatment                      
                              
 Doxorubicin                          
  228 (50.1)       156 (50.3)      
 Doxorubicin + ifosfamide                 
  227 (49.9)       154 (49.7)      
Gender                           
                              
 Male                          
  217 (47.7)       148 (47.7)      
 Female                        
  238 (52.3)       162 (52.3)      
Age                            
                              
 < 40 yrs                      
  112 (24.6)        73 (23.5)      
 40-49 yrs                     
  148 (32.5)        94 (30.3)      
 >= 50 yrs                     
  195 (42.9)       143 (46.1)      
Performance status             
                              
 0                             
  252 (55.4)       176 (56.8)      
 1                             
  201 (44.2)       134 (43.2)      
 2                             
  2 (0.4)          0 (0.0) 
Time since initial diagnosis   
                              
 < 3 m                         
  156 (34.3)        95 (30.6)      
 3-12 m                        
  128 (28.1)        96 (31.0)      
 > 12 m                        
  171 (37.6)       119 (38.4)      
Tumor grade (central review)           
                             
 I                           
   18 (4.0)           0 (0.0)        
 II                  
  131 (28.8)       128 (41.3)      
 III                          
  190 (41.8)       182 (58.7)      
 Not assessed/Unknown                  
   116 (25.5)         0 (0.0)        
Histological subtype (central review)  
                              
 Liposarcoma                   
   34 (7.5)          25 (8.1)       
 Leiomyosarcoma                
   85 (18.7)         74 (23.9)      
 Synovial sarcoma              
   54 (11.9)         52 (16.8)      
                UPS 58 (12.7) 55 (17.7) 
 Other                         
  117 (25.7)       104 (33.5)      
 Not a sarcoma                 
    6 (1.3)           0 (0.0)        
 Missing                       
  101 (22.2)         0 (0.0)        
Liver metastases               
   80 (17.6)         53 (17.1)      
Lung metastases                
  310 (68.1)       227 (73.2)      
Bone metastases                
   65 (14.3)         44 (14.2)      
Other metastases               
  360 (79.1)       239 (77.1)      
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Table 2: Prognostic factors for best overall response (CR + PR) ʹ multivariate analysis stratified by 
treatment 
  Full Multivariate Model 
Reduced Model 
stepwise selection 
Parameter Levels 
Odds Ratio 
(95% CI) P-value 
Odds Ratio 
(95% CI) P-value 
Gender                           Male               1.00  0.223   
                               Female             1.47 (0.79, 2.74)     
Age                            < 40 yrs           1.00  0.752   
                               40-49 yrs          1.14 (0.49, 2.67)     
                               >= 50 yrs          0.87 (0.37, 2.05)     
Performance status             0                  1.00  0.907   
                               1                  0.96 (0.53, 1.76)     
Time since initial diagnosis   < 3 months              1.00  0.728   
                               3-12 months              0.76 (0.34, 1.66)     
                               > 12 months              0.98 (0.46, 2.07)     
Histological grade II       1.00  0.267   
(central review)                              III               1.43 (0.76, 2.67)     
Histological subtype Liposarcoma        1.00  0.004      1.00                     0.014 
(central review)                              Leiomyosarcoma     0.14 (0.04, 0.45)   0.21 (0.08, 0.59)  
                               Synovial sarcoma   0.19 (0.06, 0.63)   0.30 (0.11, 0.84)  
 UPS  0.20 (0.06, 0.62)   0.29 (0.10, 0.81)  
 Other 0.12 (0.04, 0.36)  0.19 (0.07, 0.50)  
Liver metastases               No                 1.00  0.180   
                               Yes                0.53 (0.21, 1.35)     
Lung metastases                No                 1.00  0.140   
                               Yes                1.85 (0.82, 4.19)     
Bone metastases                No                 1.00  0.317   
                               Yes                1.56 (0.65, 3.72)     
Other metastases                         No                 1.00  0.020      1.00                     0.006 
                               Yes                0.44 (0.22, 0.88)   0.42 (0.23, 0.78)  
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Table 3: Prognostic factor analysis for OS ʹ multivariate stratified by treatment 
  Full Multivariate Model 
Reduced Model 
stepwise selection 
Parameter Levels 
Hazard Ratio 
(95% CI) P-value 
Hazard Ratio 
(95% CI) P-value 
Gender                            Male               1.00  0.064   
                               Female             0.78 (0.60, 1.01)     
Age                            < 40 yrs           1.00  0.502   
                               40-49 yrs          1.17 (0.80, 1.71)     
                               >= 50 yrs          1.25 (0.86, 1.82)     
Performance status             0                  1.00  0.017   
                               1                  1.37 (1.06, 1.77)     
Time since initial diagnosis   < 3 months              1.00  0.014   
                               3-12 months             1.49 (1.08, 2.07)     
                               > 12 months             0.99 (0.72, 1.35)     
Histological grade II       1.00  0.240   
(central review)                        III               1.17 (0.90, 1.50)     
Histological subtype Liposarcoma        1.00  0.257   
(central review)                        Leiomyosarcoma     1.78 (1.04, 3.02)     
 Synovial sarcoma   1.60 (0.90, 2.86)     
                               UPS 1.77 (1.02, 3.07)     
                               Other              1.74 (1.05, 2.90)     
Liver metastases               No                 1.00  0.230   
                               Yes                1.23 (0.88, 1.73)     
Lung metastases                No                 1.00  0.712   
                               Yes                1.06 (0.79, 1.42)     
Bone metastases                No                 1.00  0.052       1.00           0.003 
                               Yes                1.44 (1.00, 2.07)    1.56 (1.16, 2.09)  
Other metastases               No                 1.00  0.198 
  
                               Yes                1.23 (0.90, 1.69)   
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Table 4: Interaction of histological subtype on response to treatment (A: local pathology assessment; 
B: central pathology assessment) 
A. 
Histological subtype 
(local) 
 
Total 
(N=310) 
N (%) 
Doxo 
Responders 
(N = 22) 
N (row %) 
 
Total 
(N = 156) 
N (column %) 
DxIf 
Responders 
(N = 44) 
N (row %) 
 
Total 
(N = 154) 
N (column %) 
OR (95% CI) 
Liposarcoma 31 (10) 6 (37.5) 16 (10.3) 5 (33.3) 15 (9.7) 0.83 (0.19, 3.64) 
Leiomyosarcoma 80 (26) 4 (10.5) 38 (24.4) 9 (21.4) 42 (27.3) 2.32 (0.65, 8.27) 
Synovial sarcoma 50 (16) 3 (11.1) 27 (17.3) 10 (43.5) 23 (14.9) 6.15 (1.43, 26.39) 
UPS 30 (10) 3 (16.7) 18 (11.5) 2 (16.7) 12 (7.8) 1.00 (0.14, 7.10) 
Other 119 (38) 6 (10.5) 57 (36.5) 18 (29.0) 62 (40.3) 3.48 (1.27, 9.53) 
 
B. 
Histological subtype 
(central) 
 
Total 
(N=310) 
N (%) 
Doxo 
Responders 
(N = 22) 
N (row %) 
 
Total 
(N = 156) 
N (column %) 
DxIf 
Responders 
(N = 44) 
N (row %) 
 
Total 
(N = 154) 
N (column %) 
OR (95% CI) 
Liposarcoma 25 (8)     7 (50.0)           14 (9.0)              5 (45.5)             11 (7.1)          0.83 (0.17, 4.06) 
Leiomyosarcoma 74 (24)     4 (12.5)           32 (20.5)              8 (19.0)             42 (27.3)          1.65 (0.45, 6.05) 
Synovial sarcoma 52 (17)     4 (16.0)           25 (16.0)              9 (33.3)             27 (17.5)          2.63 (0.69, 9.98) 
UPS  55 (18)     2 (6.9)             29 (18.6)             11 (42.3)           26 (16.9)          9.90 (1.93, 50.7) 
Other 104 (33)     5 (8.9)             56 (35.9)             11 (22.9)           48 (31.2)          3.03 (0.97, 9.47) 
 
 
 
 
